Mandate

Vinge advises Artimplant in connection with new share issue

August 03, 2010

The board of directors of Artimplant AB (publ) has resolved to recommend that an extraordinary shareholders’ meeting adopt a resolution in respect of a rights issue to the existing members in order to provide the company with SEK 40,000,000 after issue costs.

Artimplant is listed on NASDAQ OMX Stockholm.

Vinge’s team primarily consisted of responsible partner Anders Strid and associates Anna Björk Larson and Emma Kero Ljungberg.

Related

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).
July 18, 2025

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025